Renewed Confidence In Data, Launches Drive J.P. Morgan Stocks
This article was originally published in The Pink Sheet Daily
Several big and mid-cap biopharmas successfully maneuvered at the seminal conference for the industry, garnering sizeable stock moves as a reward. But it’s not clear yet if the market upswing signals continued sector momentum or a brief peak.
You may also be interested in...
TMC reported successful top-line data from its Phase III PHOENIX study of its anticlotting drug cangrelor and expects to file an NDA this year.
Europe's top scientific advisory panel backed Lundbeck's alcoholism therapy Selincro (nalmefene) and Roche's next-generation breast cancer therapy Perjeta (pertuzumab) but rejected Genzyme/Isis' antisense therapy Kynamro (mipomersen) and Vanda's Fanaptum (oral iloperidone).